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Lupus nephritis affects up to 60% of adults and 80% of children with lupus. Despite vast
improvements in the survival and well being of patients with this disease our current
understanding of its pathogenesis is incomplete and the risk of end stage renal disease is still
unacceptably high.
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The glomerular lesions of lupus nephritis have been intensively studied over the last 5
decades, with the establishment and refinement of the ISN/RPS system for classifying the
glomerular lesions as well as the development of composite indices of activity and
chronicity. Classification of glomerular lesions in SLE was initially based on 5 year
outcomes in patients who were untreated except for corticosteroids. Using patient survival as
the outcome it was clear that patients with focal glomerular disease or membranous disease
progressed slowly and had a much better outcome at 5 years than those with diffuse disease
most of whom succumbed within 2 years. The validation of the current classification criteria
and of activity and chronicity indices for determining treatment and predicting long-term
(>5 year) outcomes in the current era of optimized immunologic and medical interventions
is still a work in progress. This is in part because outcome is linked to demographic factors
including age, gender and ethnicity as well as compliance, responsiveness to therapy and
number of relapses; these currently cannot be predicted from an initial renal biopsy.
Compared with the emphasis on glomerular lesions in lupus biopsies, less attention has
historically been paid to lesions of the renal tubulointerstitial compartment that include
infiltrates with mononuclear cells, tubular atrophy, fibrosis and tubular immune complex
deposition. Several previous studies found that tubulointerstitial lesions correlate with
glomerular injury (1-2). A recent study from Clark's group did not however find a clear
association between the magnitude of tubulointerstitial infiltrates and either activity index or
glomerular histologic class but rather with the tubular components of the chronicity score
that include tubular atrophy and fibrosis (3). In addition there is consensus that the presence
of infiltrates does not correlate with the degree of interstitial immune complex deposition. It
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is currently not possible to predict clinically which patients will have tubulointerstitial
infiltrates.
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Interstitial fibrosis is a component of the chronicity score and is recognized as a poor
prognostic indicator in lupus nephritis. There is also strong agreement in the literature that
the presence of tubulointerstitial infiltrates independently correlates with a worse long-term
outcome (1-2, 4). Early studies indicated that tubulointerstitial infiltrates were associated
with poorer glomerular function at presentation and poorer long-term outcome and that
glomerular function at follow up correlated with the numbers of monocytes/macrophages in
the initial biopsy. These findings were confirmed recently by Hsieh et al who found that
tubulointerstitial inflammation was associated with a decreased GFR and higher serum
creatinine at the time of biopsy but that a predominance of B or T cells per se did not
correlate with either of these variables (3). Strikingly, 37% of patients with severe
tubulointerstitial inflammation at biopsy progressed to renal failure in 24 months. Histologic
involvement of the tubulointerstitial compartment has been observed in repeat biopsies even
from patients in clinical remission. Poor long term outcomes were particularly noted when
interstitial infiltrates of mononuclear cells were still present at a second biopsy (5).
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Considerable recent interest has focused on the distribution and composition of the
tubulointerstitial infiltrates in lupus biopsies as well as their effector functions. Lymphocytic
infiltrates in lupus nephritis kidneys are heterogeneous in their anatomic structure with
≈50% of biopsies manifesting scattered infiltrates of B cells and plasma cells and 50%
manifesting T:B aggregates that often accumulate in the periglomerular areas (6-8). Studies
of the cellular composition of these infiltrates have shown that T cells, both CD4 and CD8,
are the dominant cell type although B cells, NK cells and plasma cells are also found. There
is extensive heterogeneity among patients with some patients having predominantly CD8
and others CD4 infiltrates. An extensive analysis of T cell infiltrates from 17 human SLE
renal biopsies found that T cells are present both in periglomerular regions and in the
interstitium with a somewhat different anatomic distribution and potentially different
function of renal CD4 and CD8 T cells (9). Both Th1 and TH17 T cells have been identified
in biopsies of patients with proliferative lupus nephritis. B cells are present in 50-60% of
biopsies (6, 9) but germinal center formation occurs rarely, being found in 0/192 biopsies
studied by Shen (6) and only 4/68 (6%) of biopsies studied by Clark's group (8).
Macrophages/monocytes accumulate widely throughout the interstitium and may be found
in the glomeruli, particularly in individuals with proliferative disease. There is an increasing
appreciation that several subsets of dendritic cells can also infiltrate inflamed kidneys.
One important question is whether tubulointerstitial infiltrates are induced by or directed to
renal antigens and therefore constitute a secondary aspect of autoimmunity that could
generate long-lived organ specific memory/effector cells. The T cell aspect of this question
was recently addressed by Winchester et al. who found that both CD4 and CD8 T cell
infiltrates from lupus biopsies are oligoclonal (9). Clonal CD4 populations were found in
periglomerular aggregates that also contain B cells, raising the possibility that such clones
could provide help for B cells. The identification of B cell and plasma cell clusters in close
proximity to ICOS+ TFH like T cells lends credence to this hypothesis (7, 10). In addition,
clonal expansions of CD8+/CD28null memory effector cells were shared among multiple
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renal compartments and/or the peripheral blood. Which antigens are driving this response
has not yet been addressed.
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In a manuscript published in this issue of Arthritis and Rheumatology, Kinloch et al have
asked which antigens drive the expansion of tubulointerstitial B cells (insert reference here).
Previously this group sampled single B cells from T:B aggregates of 9 human SLE biopsies
and found both clonal relationships and somatic mutations, evidence that T cell driven
clonal expansion of B cells is occurring in situ (8). They have now extended their studies by
co-expressing the heavy and light chains of 25 single B cells harvested by laser capture
microscopy or single cell sorting and testing them for antigenic specificity. These cells are
representative of clonal expansions from 8 different lupus biopsies, 7 with T cell:B cell
aggregates and one with germinal center structures. Many previous studies of antibodies
eluted from lupus biopsies, both mouse and human, have shown that a large proportion do
not bind classical lupus autoantigens. Indeed, the group found by screening on HEp-2 cells
that <20% of the reconstituted antibodies reacted with nuclear autoantigens whereas ≈40%
reacted with structures in the cytoplasm and the rest had no reactivity. They then used two
separate approaches to identify the putative autoantigens; the first was to screen the
antibodies on commercial arrays displaying >9000 human proteins and the second was to
perform immunoprecipitation with HEp-2 lysates followed by mass spectrometry. Most of
the anti-cytoplasmic antibodies recognized fewer than 8 of the 9000 proteins on the
proteome arrays, indicating that the local production of antibodies is driven by a limited
number of antigens. When the two assays were cross-referenced, vimentin was the only
shared putative autoantigen. Using co-localization studies with an anti-vimentin antibody
and direct binding to vimentin coated slides the group confirmed that 10/11 of the antibodies
with cytoplasmic reactivity could bind to vimentin. In accord with this finding they showed
an increase in vimentin expression in biopsy samples with localization to a subset of cells
within the interstitial infiltrates and a correlation between high serum titers of anti-vimentin
antibodies and severe tubulointerstitial infiltrates.
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These painstaking experiments by both Winchester and Kinloch represent a major advance
in our ability to garner mechanistic information from vanishingly small samples of archived
tissue and represent only the beginning of new technologies that can extract vast quantities
of data from single cells. Together, the studies suggest that clonal expansion of both B and T
cells occurs in situ within the renal interstitium and may be driven by local autoantigens.
Furthermore these immune responses are likely to contribute to disease pathogenesis.
Experiments in a mouse model of inflammatory glomerulonephritis have illustrated how a T
cell directed immune response to a model renal antigen expressed in the glomeruli amplifies
renal inflammation in a manner dependent on both peripheral and local dendritic cells; the
ongoing immune response helps to recruit and maintain periglomerular infiltrates,
promulgates an increase in infiltrating renal macrophages and dendritic cells and causes
chronic tubulointerstitial damage (11). These experiments suggest that the infiltrates are not
just biomarkers of more severe disease but that they play a causative role in disease
progression.
It should not come as a surprise that many of the B cells in inflamed lupus nephritis kidneys
are making antibodies directed at vimentin, a major component of the intermediate filament

Arthritis Rheumatol. Author manuscript; available in PMC 2015 December 01.

Davidson

Page 4

NIH-PA Author Manuscript
NIH-PA Author Manuscript

protein produced by cells of mesenchymal origin. Antibodies to vimentin have been found
in a variety of inflammatory and autoimmune conditions including RA and mouse models of
SLE as well as in allograft rejection. Several experimental approaches have suggested
potential mechanisms by which tolerance to vimentin is broken during inflammation
[reviewed (12)]. First, cleavage of vimentin is one of the first steps in dismantling the
cytoskeleton during the early stages apoptosis. Thus sites of inflammation and tissue damage
are sources of vimentin fragments. Post-translational modifications such as citrullination and
shedding of soluble fragments could also contribute to the exposure of cryptic immunogenic
epitopes. In rheumatoid arthritis for example, vimentin fragments are found in synovial fluid
and antibodies to citrullinated vimentin are as common as antibodies to CCP and correlate
with disease activity. Although intact intermediate filaments are intracellular, vimentin or its
fragments are expressed on the cell surfaces of activated macrophages, platelets, and
apoptotic T lymphocytes, and neutrophils, where they can act both as immunogens and as
targets of circulating autoantibodies. Vimentin is also expressed by injured endothelium and
tubular cells. Of renal allograft transplant recipients, approximately 50% develop IgM and
12-25% develop IgG anti-vimentin antibodies despite conventional immunosuppression
(13). In humans with glomerular diseases, including SLE, vimentin is found in the renal
interstitium and correlates with declining GFR (14), consistent with the findings of Kinloch
et al. In addition, the quantity of vimentin mRNA in urine pellets from allograft recipients is
highly associated with tubulointerstial fibrosis and tubular atrophy (15).
Abundant evidence suggests that antibodies to vimentin have pathogenic potential. Preimmunization with vimentin accelerates allograft rejection and graft vasculopathy in murine
models in an antibody dependent fashion. IgM anti-vimentin antibodies can fix complement
and colocalization of vimentin and complement on apoptosing leukocytes and plateletleukocyte conjugates has been observed in rejecting allografts. Notably, this does not occur
in isografts, suggesting that tissue damage and vimentin exposure is necessary for antibody
mediated damage to occur. The interaction of anti-vimentin antibodies with platelets
accelerates intimal occlusion in cardiac allografts, a result of platelet activation by antivimentin antibodies [reviewed (12)].
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The findings of Kinloch et al raise several important considerations with respect to lupus
nephritis. First, antibodies to vimentin appear to belong to a group of antibodies arising in
response to antigens within damaged tissue that have potential for amplification of tissue
damage. Whether or not anti-vimentin T cells are also elicited and what other antigens may
elicit similar responses, including others identified in allograft recipients, remain to be
determined. Several additional potential renal auto antigens were identified by Kinloch et al
and need to undergo further validation. Importantly, these types of immune responses to
renal antigens could result in subsequent memory autoimmune responses that are reactivated
following any renal insult independently of lupus specific anti-nuclear responses.
The progression from acute kidney injury to chronic renal disease is influenced by many
intrarenal factors including glomerular hypertension, endothelial injury and vascular
dropout, interstitial inflammation and fibrosis and epigenetic changes within renal cell
subpopulations. These mechanisms amplify each other and can be exacerbated by repeated
injury. How the anti-vimentin response contributes to this process can now be investigated
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in well characterized cohorts of lupus nephritis patients. We need to understand which
patients express this specificity, whether these antibodies increase over time and whether
either they or urine vimentin mRNA predict outcome or are biomarkers for deteriorating
renal function. Importantly, high titer anti-vimentin antibodies 1 year after renal transplant
are associated with allograft associated coronary artery disease 4 years later (13) . The
factors contributing to this outcome are not currently understood but the implication of this
finding for lupus nephritis patients is clear and bears further examination.
Given the ubiquity of anti-vimentin antibodies in allograft recipients and their potential
pathogenic role, several studies have examined whether the emergence of these antibodies
can be prevented by immunosuppression. Notably, formation of these antibodies in human
allograft recipients is not prevented by cyclosporine and is suppressed to a greater degree by
MMF than by azathioprine. Mouse studies have indicated that costimulatory blockade also
delays the production of IgG anti-vimentin antibodies in allograft recipients [reviewed (13)].
Should these autoantibodies arise during or after the onset of lupus nephritis further studies
to address how they can be prevented and whether this has an effect on long-term outcomes
would then be warranted.
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